Read our independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Our work is reader-supported. Sign up to our free or paid plans here.
In this interview with Psychedelic Alpha’s Josh Hardman, psychiatrist, therapist and researcher Dr. Óscar Soto discusses psychedelic trial design, therapeutic fidelity, and the evolving role of subjective experience in psychedelics and psychiatry. He also shares his views from the field, with a particular focus on clinical trials of 5-MeO-DMT.
This morning, AtaiBeckley shared positive topline data from the open-label portion of its Phase 2b trial of intranasal 5-MeO-DMT (BPL-003) in patients with treatment-resistant depression (TRD), which offered a second dose to many participants. That second dose, it reports, led to additional rapid antidepressant effects that were sustained for up to 8 weeks. We reviewed the readout and spoke with CEO, Srinivas Rao, to dive a little deeper…
Compass Pathways Accelerates Psilocybin Launch Plans by Almost a Year • Australia’s VA Will Fund Psychedelic-Assisted Psychotherapy for Veterans • AbbVie Paid $900M Upfront for Gilgamesh’s Psychedelic Candidate • AtaiBeckly Is Born • MindMed Closes $259M Public Offering • European Psychedelics Group Pens Letter to European Commission President • and more…
This morning, Compass Pathways announced that it is preparing to launch its psilocybin therapy (COMP360) for treatment-resistant depression (TRD) at least nine months earlier than previously planned, following a “positive” September meeting with FDA. Here, we delve much deeper into this breaking news, which we discussed with the Compass CEO, Kabir Nath, earlier today.
Delix Therapeutics Posts Early Efficacy Signal for ‘Non-Hallucinogenic’ Neuroplastogen as FDA Clears At-Home Phase II • NRx Pharmaceuticals Wants FDA to Ban Its Competitors’ Ketamine • Cybin Trades Toxic Financing for Top Tier Investors in $175M Raise • and more…
Each quarter, we provide a look at federal lobbying disclosures by psychedelic drug developers and nonprofits. Here, we share our analysis of the latest developments for our Pα+ subscribers.
Through our years of reporting we have covered many of the topics we believe to be important to the present and future of the psychedelics space, broadly defined. However, much of this commentary is scattered across Bulletins, deep dives, special reports and year-end reviews.
The Library provides digestible explainers on salient topics across psychedelic drug development, policy and business: from basic explainers such as “what is psychedelic-assisted therapy?” through to more complex matters such as REMS programs and bifurcated scheduling.
It’s exclusively available to our Pα+ subscribers, with new content added regularly.
Pα+ Library: we introduce some of the key concepts in the matter of bifurcated scheduling; a process by which an approved drug product may be placed in a different schedule to the substance itself. As we discuss in this piece, this could have significant repercussions for psychedelic research, legality, and even taxes.
Pα+ Library: we sketch out what a psychedelic REMS might look like, highlighting how these programs could have an outsized impact on the post-approval delivery and accessibility of these treatments.
The Psychedelic Practitioner by Psychedelic Alpha is a new publication designed specifically for therapists, clinicians, facilitators, and other professionals working with—or preparing to work with—psychedelic therapies and related treatments.
The Psychedelic Practitioner by Psychedelic Alpha is a new publication designed specifically for therapists, clinicians, facilitators, and other professionals working with—or preparing to work with—psychedelic therapies and related treatments.
Archived versions of our Psychedelic News Feed.
Your one-stop digest for the latest coverage of psychedelics business, policy, research and beyond, for the week commencing October 27, 2025.
Your one-stop digest for the latest coverage of psychedelics business, policy, research and beyond, for the week commencing October 20, 2025.
Your one-stop digest for the latest coverage of psychedelics business, policy, research and beyond, for the week commencing October 13, 2025.
Your one-stop digest for the latest coverage of psychedelics business, policy, research and beyond, for the week commencing October 6, 2025.
Your one-stop digest for the latest coverage of psychedelics business, policy, research and beyond, for the week commencing September 29, 2025.
Your one-stop digest for the latest coverage of psychedelics business, policy, research and beyond, for the week commencing September 22, 2025.
Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond
Insights and interviews delivered to your inbox. No spam, just valuable information.
